Tecovirimat (ST-246) Treatment for Orthopox Virus Exposure
Conditions: Smallpox; MonkeypoxIntervention: Drug: TecovirimatSponsor: U.S. Army Medical Research and Materiel CommandAvailable - verified April 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 4, 2014 Category: Research Source Type: clinical trials
Tecovirimat (ST-246) Treatment for Orthopox Virus Exposure
Conditions: Smallpox; MonkeypoxIntervention: Drug: TecovirimatSponsor: U.S. Army Medical Research and Materiel CommandAvailable - verified November 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 4, 2014 Category: Research Source Type: clinical trials
Tecovirimat (ST-246) Treatment for Orthopox Virus Exposure
Conditions: Smallpox; MonkeypoxIntervention: Drug: TecovirimatSponsor: U.S. Army Medical Research and Materiel CommandAvailable - verified April 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 4, 2014 Category: Research Source Type: clinical trials
Tecovirimat (ST-246) Treatment for Orthopox Virus Exposure
Conditions: Smallpox; MonkeypoxIntervention: Drug: TecovirimatSponsor: U.S. Army Medical Research and Materiel CommandAvailable - verified November 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 4, 2014 Category: Research Source Type: clinical trials
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Condition: SmallpoxIntervention: Biological: MVA-BN® smallpox vaccineSponsor: Bavarian NordicRecruiting - verified December 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 15, 2014 Category: Research Source Type: clinical trials
A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000®
Condition: 18-42 Year Old Healthy Vaccinia-naïve SubjectsInterventions: Biological: MVA BN®; Biological: ACAM2000®Sponsors: Bavarian Nordic; United States Army Medical Research Institute of Infectious DiseasesRecruiting - verified March 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 26, 2013 Category: Research Source Type: clinical trials
A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects
Condition: SmallpoxInterventions: Biological: LF formulation of IMVAMUNE®; Biological: FD formulation of IMVAMUNE®Sponsor: Bavarian NordicCompleted - verified September 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 14, 2012 Category: Research Source Type: clinical trials
VA-005 Clinical Outcomes of VIGIV Treatment of Smallpox Vaccination Complications or Vaccinia Infection
Condition: Complication of Smallpox VaccinationIntervention: Biological: VIGIVSponsors: Cangene Corporation; Centers for Disease Control and PreventionEnrolling by invitation - verified April 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 14, 2011 Category: Research Source Type: clinical trials
A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects
Condition: SmallpoxInterventions: Biological: IMVAMUNE; Biological: IMVAMUNE; Biological: IMVAMUNE; Other: PlaceboSponsor: Bavarian NordicCompleted - verified December 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 14, 2010 Category: Research Source Type: clinical trials
